Alzheimer's disease-emerging new potential therapeutic modalities

摘要

The recent article by Salloway et al was interesting.1 Interestingly, a number of new targets have been identified, which may play a potential role in decreasing the cognitive deficits seen in patients with Alzheimer's disease (AD).For instance, diosgenin has recently been shown to attenuate the pathological lesions in AD. It does this by activating the 1, 25D (3)-MARRS/Pdia3/ERp57 pathway.2 Similarly, recent studies indicate that striatal-enriched protein tyrosine phospha-tase (STEP) may be involved in the pathogenesis of AD.3 Modulation of STEP may play a major role in attenuating the risk of AD. Scyllo-inositol is another new agent that decreases neuronal toxicity by promoting low-molecular-weight Abeta and neutralizing Abeta trimers.